These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11254825)

  • 1. Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis.
    Haworth CS; Selby PL; Adams JE; Mawer EB; Horrocks AW; Webb AK
    Thorax; 2001 Apr; 56(4):314-6. PubMed ID: 11254825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
    Bartram SA; Peaston RT; Rawlings DJ; Francis RM; Thompson NP
    Aliment Pharmacol Ther; 2003 Dec; 18(11-12):1121-7. PubMed ID: 14653832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates for osteoporosis in people with cystic fibrosis.
    Brenckmann C; Papaioannou A
    Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis.
    Haworth CS; Jones AM; Adams JE; Selby PL; Webb AK
    J Cyst Fibros; 2004 Dec; 3(4):233-6. PubMed ID: 15698940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation.
    Aris RM; Lester GE; Renner JB; Winders A; Denene Blackwood A; Lark RK; Ontjes DA
    Am J Respir Crit Care Med; 2000 Sep; 162(3 Pt 1):941-6. PubMed ID: 10988110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
    Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
    Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
    Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
    Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest.
    Watanabe Y; Ohshima H; Mizuno K; Sekiguchi C; Fukunaga M; Kohri K; Rittweger J; Felsenberg D; Matsumoto T; Nakamura T
    J Bone Miner Res; 2004 Nov; 19(11):1771-8. PubMed ID: 15476576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
    Vis M; Bultink IE; Dijkmans BA; Lems WF
    Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC; Deley M; Van Der Spek M; Verberne HJ; Van Deventer SJ; Hommes DW
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.
    Haworth CS; Selby PL; Webb AK; Mawer EB; Adams JE; Freemont TJ
    Lancet; 1998 Nov; 352(9142):1753-4. PubMed ID: 9848356
    [No Abstract]   [Full Text] [Related]  

  • 13. Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.
    Cauza E; Etemad M; Winkler F; Hanusch-Enserer U; Partsch G; Noske H; Dunky A
    J Clin Pharm Ther; 2004 Oct; 29(5):431-6. PubMed ID: 15482386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of postoperative osteopenia using IV pamidronate: a pilot study.
    Hobby BD; Dominguez-Bartmess S; Szalay EA
    J Pediatr Orthop; 2013; 33(7):763-7. PubMed ID: 23872799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate.
    Trombetti A; Gerbase MW; Spiliopoulos A; Slosman DO; Nicod LP; Rizzoli R
    J Heart Lung Transplant; 2000 Aug; 19(8):736-43. PubMed ID: 10967266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
    Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
    Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pamidronate therapy as prevention of bone loss following renal transplantation.
    Fan SL; Almond MK; Ball E; Evans K; Cunningham J
    Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium.
    Stewart GO; Gutteridge DH; Price RI; Ward L; Retallack RW; Prince RL; Stuckey BG; Kent GN; Bhagat CI; Dhaliwal SS
    Bone; 1999 Feb; 24(2):139-44. PubMed ID: 9951784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF).
    Chapman I; Greville H; Ebeling PR; King SJ; Kotsimbos T; Nugent P; Player R; Topliss DJ; Warner J; Wilson JW
    Clin Endocrinol (Oxf); 2009 Jun; 70(6):838-46. PubMed ID: 18823395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone density changes in Paget's disease 2 years after iv pamidronate: profound, sustained increases in pagetic bone with severity-related loss in forearm nonpagetic cortical bone.
    Gutteridge DH; Retallack RW; Ward LC; Price RI; Stewart GO; Stuckey BG; Prince RL; Kent GN; Bhagat CI; Thompson RI; Nicholson GC
    Bone; 2003 Jan; 32(1):56-61. PubMed ID: 12584036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.